Subject 0 7 0 7 O
has 8 11 8 11 O
an 12 14 12 14 O
Eastern 15 22 15 22 B-clinical_variable
Cooperative 23 34 23 34 I-clinical_variable
Oncology 35 43 35 43 I-clinical_variable
Group 44 49 44 49 I-clinical_variable
( 50 51 50 51 I-clinical_variable
ECOG 51 55 51 55 I-clinical_variable
) 55 56 55 56 I-clinical_variable
Performance 57 68 57 68 I-clinical_variable
Status 69 75 69 75 I-clinical_variable
of 76 78 76 78 O
0 79 80 79 80 B-lower_bound
to 81 83 81 83 O
2 84 85 84 85 B-upper_bound

Subject 0 7 86 93 O
has 8 11 94 97 O
fresh 12 17 98 103 O
and/or 18 24 104 110 O
archived 25 33 111 119 O
diagnostic 34 44 120 130 O
formalin 45 53 131 139 O
- 53 54 139 140 O
fixed 54 59 140 145 O
paraffin 60 68 146 154 O
embedded 69 77 155 163 O
( 78 79 164 165 O
FFPE 79 83 165 169 O
) 83 84 169 170 O
tumor 85 90 171 176 B-cancer
tissue 91 97 177 183 O
confirmed 98 107 184 193 O
available 108 117 194 203 O
for 118 121 204 207 O
analyses 122 130 208 216 O

Subject 0 7 217 224 O
has 8 11 225 228 O
had 12 15 229 232 O
major 16 21 233 238 B-treatment
surgery 22 29 239 246 I-treatment
within 30 36 247 253 O
21 37 39 254 256 B-upper_bound
days 40 44 257 261 I-upper_bound
prior 45 50 262 267 I-upper_bound
to 51 53 268 270 O
the 54 57 271 274 O
first 58 63 275 280 O
dose 64 68 281 285 O
of 69 71 286 288 O
ABBV-399 72 80 289 297 B-treatment

Subject 0 7 298 305 O
has 8 11 306 309 O
history 12 19 310 317 O
of 20 22 318 320 O
interstitial 23 35 321 333 B-chronic_disease
lung 36 40 334 338 I-chronic_disease
disease 41 48 339 346 I-chronic_disease
( 49 50 347 348 I-chronic_disease
ILD 50 53 348 351 I-chronic_disease
) 53 54 351 352 I-chronic_disease
or 55 57 353 355 O
pneumonitis 58 69 356 367 B-chronic_disease
that 70 74 368 372 O
required 75 83 373 381 O
treatment 84 93 382 391 B-treatment
with 94 98 392 396 I-treatment
systemic 99 107 397 405 I-treatment
steroids 108 116 406 414 I-treatment
, 116 117 414 415 O
or 118 120 416 418 O
any 121 124 419 422 O
evidence 125 133 423 431 O
of 134 136 432 434 O
active 137 143 435 441 O
ILD 144 147 442 445 O
or 148 150 446 448 O
pneumonitis 151 162 449 460 O

Subject 0 7 461 468 O
has 8 11 469 472 O
history 12 19 473 480 O
of 20 22 481 483 O
major 23 28 484 489 O
immunologic 29 40 490 501 O
reaction 41 49 502 510 O
to 50 52 511 513 O
any 53 56 514 517 O
Immunoglobulin 57 71 518 532 B-treatment
G 72 73 533 534 I-treatment
( 74 75 535 536 I-treatment
IgG 75 78 536 539 I-treatment
) 78 79 539 540 I-treatment
containing 80 90 541 551 I-treatment
agent 91 96 552 557 I-treatment

Subject 0 7 558 565 O
has 8 11 566 569 O
received 12 20 570 578 O
anticancer 21 31 579 589 B-treatment
therapy 32 39 590 597 I-treatment
including 40 49 598 607 O
chemotherapy 50 62 608 620 B-treatment
, 62 63 620 621 O
radiation 64 73 622 631 B-treatment
therapy 74 81 632 639 I-treatment
, 81 82 639 640 O
immunotherapy 83 96 641 654 B-treatment
, 96 97 654 655 O
biologic 98 106 656 664 B-treatment
, 106 107 664 665 O
or 108 110 666 668 O
any 111 114 669 672 O
investigational 115 130 673 688 B-treatment
therapy 131 138 689 696 I-treatment
within 139 145 697 703 O
a 146 147 704 705 O
period 148 154 706 712 O
of 155 157 713 715 O
21 158 160 716 718 B-upper_bound
days 161 165 719 723 I-upper_bound
or 166 168 724 726 O
herbal 169 175 727 733 B-treatment
therapy 176 183 734 741 I-treatment
within 184 190 742 748 O
7 191 192 749 750 B-upper_bound
days 193 197 751 755 I-upper_bound
prior 198 203 756 761 I-upper_bound
to 204 206 762 764 O
the 207 210 765 768 O
first 211 216 769 774 O
dose 217 221 775 779 O
of 222 224 780 782 O
ABBV-399 225 233 783 791 B-treatment

Subject 0 7 792 799 O
has 8 11 800 803 O
uncontrolled 12 24 804 816 O
metastases 25 35 817 827 B-cancer
to 36 38 828 830 O
the 39 42 831 834 O
central 43 50 835 842 O
nervous 51 58 843 850 O
system 59 65 851 857 O
( 66 67 858 859 O
CNS 67 70 859 862 O
) 70 71 862 863 O
based 72 77 864 869 O
on 78 80 870 872 O
head 81 85 873 877 O
CT 86 88 878 880 B-treatment
or 89 91 881 883 O
MRI 92 95 884 887 B-treatment

Subject 0 7 888 895 O
has 8 11 896 899 O
unresolved 12 22 900 910 O
clinically 23 33 911 921 O
significant 34 45 922 933 O
adverse 46 53 934 941 B-clinical_variable
events 54 60 942 948 I-clinical_variable
> 61 62 949 950 O
= 62 63 950 951 O
Grade 64 69 952 957 B-lower_bound
2 70 71 958 959 I-lower_bound
from 72 76 960 964 O
prior 77 82 965 970 B-treatment
anticancer 83 93 971 981 I-treatment
therapy 94 101 982 989 I-treatment
, 101 102 989 990 O
except 103 109 991 997 O
for 110 113 998 1001 O
alopecia 114 122 1002 1010 B-chronic_disease
or 123 125 1011 1013 O
anemia 126 132 1014 1020 B-chronic_disease

Subject 0 7 1021 1028 O
must 8 12 1029 1033 O
have 13 17 1034 1038 O
advanced 18 26 1039 1047 O
Non 27 30 1048 1051 B-cancer
- 30 31 1051 1052 I-cancer
Small 31 36 1052 1057 I-cancer
Cell 37 41 1058 1062 I-cancer
Lung 42 46 1063 1067 I-cancer
Cancer 47 53 1068 1074 I-cancer
( 54 55 1075 1076 I-cancer
NSCLC 55 60 1076 1081 I-cancer
) 60 61 1081 1082 I-cancer
that 62 66 1083 1087 O
is 67 69 1088 1090 O
not 70 73 1091 1094 O
amenable 74 82 1095 1103 O
to 83 85 1104 1106 O
surgical 86 94 1107 1115 B-treatment
resection 95 104 1116 1125 I-treatment
or 105 107 1126 1128 O
other 108 113 1129 1134 O
approved 114 122 1135 1143 O
therapeutic 123 134 1144 1155 O
options 135 142 1156 1163 O
that 143 147 1164 1168 O
have 148 152 1169 1173 O
demonstrated 153 165 1174 1186 O
clinical 166 174 1187 1195 O
benefit 175 182 1196 1203 O

Subject 0 7 1204 1211 O
must 8 12 1212 1216 O
have 13 17 1217 1221 O
available 18 27 1222 1231 O
post 28 32 1232 1236 O
- 32 33 1236 1237 O
progression 33 44 1237 1248 O
tumor 45 50 1249 1254 B-cancer
tissue 51 57 1255 1261 O
for 58 61 1262 1265 O
central 62 69 1266 1273 B-treatment
c 70 71 1274 1275 I-treatment
- 71 72 1275 1276 I-treatment
Met 72 75 1276 1279 I-treatment
immunohistochemistry 76 96 1280 1300 I-treatment
( 97 98 1301 1302 I-treatment
IHC 98 101 1302 1305 I-treatment
) 101 102 1305 1306 I-treatment
testing 103 110 1307 1314 I-treatment

Subject 0 7 1315 1322 O
must 8 12 1323 1327 O
have 13 17 1328 1332 O
discontinued 18 30 1333 1345 O
osimertinib 31 42 1346 1357 B-treatment
due 43 46 1358 1361 O
to 47 49 1362 1364 O
disease 50 57 1365 1372 O
progression 58 69 1373 1384 O

Subject 0 7 1385 1392 O
must 8 12 1393 1397 O
have 13 17 1398 1402 O
metastatic 18 28 1403 1413 B-cancer
NSCLC 29 34 1414 1419 I-cancer
with 35 39 1420 1424 O
documented 40 50 1425 1435 O
Epidermal 51 60 1436 1445 O
Growth 61 67 1446 1452 O
Factor 68 74 1453 1459 O
Receptor 75 83 1460 1468 O
( 84 85 1469 1470 O
EGFR 85 89 1470 1474 O
) 89 90 1474 1475 O
mutation(s 91 101 1476 1486 O
) 101 102 1486 1487 O
known 103 108 1488 1493 O
to 109 111 1494 1496 O
be 112 114 1497 1499 O
sensitive 115 124 1500 1509 O
to 125 127 1510 1512 O
osimertinib 128 139 1513 1524 B-allergy_name
, 139 140 1524 1525 O
including 141 150 1526 1535 O
del19 151 156 1536 1541 B-allergy_name
, 156 157 1541 1542 O
L858R 158 163 1543 1548 B-allergy_name
, 163 164 1548 1549 O
G719X 165 170 1550 1555 B-allergy_name
or 171 173 1556 1558 O
L861Q 174 179 1559 1564 B-allergy_name

Subjects 0 8 1565 1573 O
enrolled 9 17 1574 1582 O
on 18 20 1583 1585 O
the 21 24 1586 1589 O
combination 25 36 1590 1601 B-treatment
therapy 37 44 1602 1609 I-treatment
phase 45 50 1610 1615 O
must 51 55 1616 1620 O
satisfy 56 63 1621 1628 O
the 64 67 1629 1632 O
above 68 73 1633 1638 O
exclusion 74 83 1639 1648 O
criteria 84 92 1649 1657 O

Subjects 0 8 1658 1666 O
in 9 11 1667 1669 O
the 12 15 1670 1673 O
combination 16 27 1674 1685 B-treatment
therapy 28 35 1686 1693 I-treatment
Arm 36 39 1694 1697 I-treatment
E 40 41 1698 1699 I-treatment

Subjects 0 8 1700 1708 O
in 9 11 1709 1711 O
the 12 15 1712 1715 O
combination 16 27 1716 1727 B-treatment
therapy 28 35 1728 1735 I-treatment
arms 36 40 1736 1740 I-treatment
A 41 42 1741 1742 I-treatment
and 43 46 1743 1746 I-treatment
D 47 48 1747 1748 I-treatment
must 49 53 1749 1753 O
be 54 56 1754 1756 O
eligible 57 65 1757 1765 O
to 66 68 1766 1768 O
receive 69 76 1769 1776 O
erlotinib 77 86 1777 1786 B-treatment
, 86 87 1786 1787 O
or 88 90 1788 1790 O
nivolumab 91 100 1791 1800 B-treatment
per 101 104 1801 1804 O
most 105 109 1805 1809 O
current 110 117 1810 1817 O
prescribing 118 129 1818 1829 O
information 130 141 1830 1841 O
, 141 142 1841 1842 O
or 143 145 1843 1845 O
at 146 148 1846 1848 O
the 149 152 1849 1852 O
discretion 153 163 1853 1863 O
of 164 166 1864 1866 O
the 167 170 1867 1870 O
Investigator 171 183 1871 1883 O

Subjects 0 8 1884 1892 O
may 9 12 1893 1896 O
not 13 16 1897 1900 O
receive 17 24 1901 1908 O
ABBV-399 25 33 1909 1917 B-treatment
in 34 36 1918 1920 O
combination 37 48 1921 1932 O
with 49 53 1933 1937 O
osimertinib 54 65 1938 1949 B-treatment
, 65 66 1949 1950 O
erlotinib 67 76 1951 1960 B-treatment
or 77 79 1961 1963 O
nivolumab 80 89 1964 1973 B-treatment
if 90 92 1974 1976 O
they 93 97 1977 1981 O
have 98 102 1982 1986 O
any 103 106 1987 1990 O
medical 107 114 1991 1998 O
condition 115 124 1999 2008 O
which 125 130 2009 2014 O
in 131 133 2015 2017 O
the 134 137 2018 2021 O
opinion 138 145 2022 2029 O
of 146 148 2030 2032 O
the 149 152 2033 2036 O
Investigator 153 165 2037 2049 O
places 166 172 2050 2056 O
the 173 176 2057 2060 O
subject 177 184 2061 2068 O
at 185 187 2069 2071 O
an 188 190 2072 2074 O
unacceptably 191 203 2075 2087 O
high 204 208 2088 2092 O
risk 209 213 2093 2097 O
for 214 217 2098 2101 O
toxicities 218 228 2102 2112 O
from 229 233 2113 2117 O
the 234 237 2118 2121 O
combination 238 249 2122 2133 O

Subjects 0 8 2134 2142 O
with 9 13 2143 2147 O
brain 14 19 2148 2153 B-chronic_disease
metastases 20 30 2154 2164 I-chronic_disease
may 31 34 2165 2168 O
be 35 37 2169 2171 O
eligible 38 46 2172 2180 O
2 47 48 2181 2182 B-lower_bound
weeks 49 54 2183 2188 I-lower_bound
after 55 60 2189 2194 I-lower_bound
definitive 61 71 2195 2205 O
therapy 72 79 2206 2213 B-treatment
to 80 82 2214 2216 O
all 83 86 2217 2220 O
known 87 92 2221 2226 O
sites 93 98 2227 2232 O
of 99 101 2233 2235 O
CNS 102 105 2236 2239 B-chronic_disease
disease 106 113 2240 2247 I-chronic_disease
provided 114 122 2248 2256 O
they 123 127 2257 2261 O
are 128 131 2262 2265 O
asymptomatic 132 144 2266 2278 O
and 145 148 2279 2282 O
either 149 155 2283 2289 O
off 156 159 2290 2293 O
or 160 162 2294 2296 O
on 163 165 2297 2299 O
a 166 167 2300 2301 O
non 168 171 2302 2305 O
- 171 172 2305 2306 O
increasing 172 182 2306 2316 O
dose 183 187 2317 2321 O
( 188 189 2322 2323 O
in 189 191 2323 2325 O
last 192 196 2326 2330 B-upper_bound
2 197 198 2331 2332 I-upper_bound
weeks 199 204 2333 2338 I-upper_bound
) 204 205 2338 2339 O
of 206 208 2340 2342 O
systemic 209 217 2343 2351 B-treatment
steroids 218 226 2352 2360 I-treatment
and 227 230 2361 2364 O
not 231 234 2365 2368 O
on 235 237 2369 2371 O
anticonvulsants 238 253 2372 2387 O
for 254 257 2388 2391 O
seizure 258 265 2392 2399 B-chronic_disease
activity 266 274 2400 2408 O
directly 275 283 2409 2417 O
related 284 291 2418 2425 O
to 292 294 2426 2428 O
progressive 295 306 2429 2440 O
CNS 307 310 2441 2444 B-cancer
metastases 311 321 2445 2455 I-cancer

Women 0 5 2456 2461 B-gender
of 6 8 2462 2464 O
childbearing 9 21 2465 2477 O
potential 22 31 2478 2487 O
must 32 36 2488 2492 O
have 37 41 2493 2497 O
a 42 43 2498 2499 O
negative 44 52 2500 2508 B-pregnancy
serum 53 58 2509 2514 I-pregnancy
pregnancy 59 68 2515 2524 I-pregnancy
test 69 73 2525 2529 O
within 74 80 2530 2536 O
14 81 83 2537 2539 B-upper_bound
days 84 88 2540 2544 I-upper_bound
prior 89 94 2545 2550 I-upper_bound
to 95 97 2551 2553 O
initiation 98 108 2554 2564 O
of 109 111 2565 2567 O
treatment 112 121 2568 2577 B-treatment

